Bo Dai

机构：Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Shanghai Cancer Institute, Shanghai Blood Center, Huashan Hospital · ORCID：0000-0003-1383-3864

发表论文 206 篇 · 总被引 5151 次 · h-index 38

代表论文

• Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape (2024 · Biomedicine & Pharmacotherapy · 被引 175)
• Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial (2022 · European Urology Oncology · 被引 74)
• Policy pathways through FinTech and green finance for low-carbon energy transition in BRICS nations (2025 · Energy Strategy Reviews · 被引 28)
• Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death (2025 · Advanced Science · 被引 25)
• CACA guidelines for holistic integrative management of prostate cancer (2024 · Holistic Integrative Oncology · 被引 22)
• A deep learning model, NAFNet, predicts adverse pathology and recurrence in prostate cancer using MRIs (2023 · npj Precision Oncology · 被引 21)